<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04015466</url>
  </required_header>
  <id_info>
    <org_study_id>LEGACY-2</org_study_id>
    <nct_id>NCT04015466</nct_id>
  </id_info>
  <brief_title>Advanced GC Multi-omic Characterization in EU and CELAC Populations</brief_title>
  <acronym>LEGACY-2</acronym>
  <official_title>Advanced GC Multi-omic Characterization in EU and CELAC Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional de Cancerologia de Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vall d'Hebron Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>INSTITUTO ALEXANDER FLEMING</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Central del IPS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO PCUP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación para la Investigación del Hospital Clínico de Valencia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study (cohort type) of advanced GC patients that will be recruited
      prospectively to study biological factors associated with the disease and relevant clinical
      outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite of multiple attempts to improve treatment in recent decades, none strategies has
      improved prognosis in locally advanced stage III and IV GC. A therapeutic approach to GC
      based on current histological and image criteria (Tumour Node Metastasis -TNM- stage) is
      insufficient. Although multiple targeted agents are currently under investigation, so far,
      only trastuzumab and ramucirumab have demonstrated efficacy in advanced GC and have a
      regulatory approval. For this reason, the identification of specific targets that could be
      susceptible for drug inhibition, is an urgent requirement. Moreover, most studies and current
      international databases on late-stage/advanced GC are largely based on Asian populations, in
      sharp contrast tumour biology and genome of EU or CELAC populations remain poorly known.

      The primary objective of this study are to:

        1. Characterize a multi-centric cohort including EU and CELAC populations diagnosed with
           advanced GC through a multi-omic approach including proteomics, genomics,
           transcriptomics, microbiome and exposome analysis due to study the determinants of GC.

        2. Identify the regional differences in EU and CELAC populations recruiting patients for
           this study for each omic characterization due to identify the high-risk group
           populations.

        3. Identify and select from the multi-omic approach those biomarkers useful for the
           development of an algorithm to guide the therapeutic approach for advanced GC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of a new diagnostic algorithm for gastric cancer that includes molecular landscape, patient history, histopathological and environmental factors, personal microbiome and immune landscape</measure>
    <time_frame>3 years</time_frame>
    <description>The project will look for an integrative diagnostic algorithm that incorporates multi-parameter inputs and apply artificial intelligence to provide more personalized risk estimates and which will form the basis for future development of a clinical tool</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proteomic analysis of gastric cancer tissue</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the expression of certain proteins using ICH and ISH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genomics (tumour next-generation sequencing)</measure>
    <time_frame>3 years</time_frame>
    <description>Determine differences in the genetic mutational profile of different populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomics (Nanostring immune gene expression panel)</measure>
    <time_frame>3 years</time_frame>
    <description>Determine differences in the genetic expression profile of different populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota sequencing (including level of Epstein-Barr virus [EBV] DNA)</measure>
    <time_frame>3 years</time_frame>
    <description>Determine differences in the microbiota profile of different populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary habits as assessed by a new study-specific questionnaire</measure>
    <time_frame>3 years</time_frame>
    <description>Determine differences in dietary habits of different populations and its correlation with risk to develop gastric cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological risk factors as assessed through medical chart review</measure>
    <time_frame>3 years</time_frame>
    <description>Determine differences in biological risk factors of different populations and its correlation with risk to develop gastric cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily routines as assessed by a new study-specific questionnaire</measure>
    <time_frame>3 years</time_frame>
    <description>Determine differences daily routines of different populations and its correlation with risk to develop gastric cancer</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients with high diagnostic suspicion of advanced GC diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients with confirmed absent of GC</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumour Blood Stool Urine Nail
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  Subjects &gt;18 years old, with high diagnostic suspicion of advanced GC diagnosis (Stage
             III and IV)

          -  Subjects &gt;18 years old to whom a gastroscopy was indicated and confirmed absent of GC.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Cases:

          -  Inclusion criteria:

               -  Subjects ≥18 years old.

               -  GC diagnosis stages III and IV (including gastroesophageal junction cancer)
                  and/or a gastroscopy indication due to the high diagnostic suspicion of GC as
                  part of the study of his disease.

               -  Has given and signed the IC to participate in this study.

          -  Exclusion criteria:

             • Patients diagnosed with GC early disease (stage I and II) suitable for resectable
             strategy.

          -  Withdrawal criteria:

               -  Patients initially recruited with high suspicion of GC diagnosis but not
                  confirmed by the pathological report.

        Controls:

          -  Inclusion criteria (only for microbiome analysis):

               -  Subjects ≥18 years old.

               -  Subjects to whom a gastroscopy is indicated within clinical care and is confirmed
                  absent of GC in the same centres will be matched in age (+/- 10 years), gender
                  and pertaining from the same region of the GC case.

               -  Has given and signed the IC to participate in this study.

          -  Exclusion criteria:

               -  Subjects from a different geographic area from the cases.

               -  Patients with high suspicion of GC.

               -  Patients with previous histopathologic diagnosis of peptic (gastric or duodenal)
                  ulcer disease and/or atrophy or intestinal metaplasia.

               -  Patients that have received antimicrobials during the 4 weeks period prior to the
                  endoscopy.

               -  Patients that have received proton pump inhibitors or H2-receptor antagonists, at
                  least 2 weeks prior to the endoscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Andrés Cervantes, MD</last_name>
    <phone>0034961973543</phone>
    <email>andres.cervantes@uv.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tania Fleitas, MD</last_name>
    <phone>0034961973543</phone>
    <email>tfleitask@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Alexander Fleming</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Católica de Chile</name>
      <address>
        <city>Santiago</city>
        <zip>8331150</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Garrido, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerología de México</name>
      <address>
        <city>Mexico</city>
        <zip>01480</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Ruiz, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VU Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Derks, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GenPat</name>
      <address>
        <city>Asunción</city>
        <country>Paraguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmelo Caballero, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Pathology and Immunology of University of Porto</name>
      <address>
        <city>Porto</city>
        <zip>4200 135</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fátima Carneiro, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Institut d'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Alsina, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Univeristario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Cervantes, Professor</last_name>
    </contact>
    <contact_backup>
      <last_name>Tania Fleitas, PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Paraguay</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>Personalized medicine</keyword>
  <keyword>Oncology</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Primary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

